NCT04718584 - the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors | Biotech Hunter

Enrollment

127

Participants

Timeline

Start Date

September 11, 2020

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2023

Conditions

Bladder CancerRenal CarcinomaAdvanced Penile Carcinoma

Interventions

DRUG

Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)

All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.

Trial Locations (1)

Unknown

RECRUITING

Dragonboat Biopharmaceutical,Co.,Ltd, Shanghai